Ascidian Therapeutics Announces First-Ever FDA approval of their Investigational New Drug (IND) ACDN-01, which Targets Rare Genetic Eye Diseases
Penn spinout Ascidian Therapeutics has achieved a significant milestone with the FDA's acceptance of their Investigational New Drug (IND) application for ACDN-01.
Carisma Therapeutics Announces First Patient Dosed in Phase 1 Clinical Trial of CT-0525, Appoints Eugene P. Kennedy as Chief Medical Officer
Carisma announced the dosing of its first patient in its Phase 1 trial for CT-0525, an innovative CAR-Monocyte therapy targeting HER2-overexpressing solid tumors.
Verismo Therapeutics Achieves FDA Clearance for Phase I Trial of its CAR T Therapy
Penn spinout Verismo Therapeutics has received FDA clearance for a Phase I trial of its CAR-T therapy, SynKIR-310.
iECURE Receives Three FDA Designations for its In Vivo Gene Insertion Program
iEcure, a gene-editing company spun out of Penn and co-founded by Dr. Wilson, has received three special designations from the FDA for its new treatment, ECUR-506.
Penn Startups Recognized in Labiotech’s List of “Eight companies spearheading Philadelphia’s biotech industry”
After emerging from stealth mode in 2023, BlueWhale aims to develop a technology platform and product portfolio that will provide the benefits of cell therapy to patients more quickly.
The Chamber of Commerce for Greater Philadelphia Recognizes the Philadelphia Region as Leader in Cell and Gene Therapy
The report highlights Penn’s significant contributions to the growth of the CGT sector in Greater Philadelphia, including spinning out over 40 CGT companies since 2018.
Philadelphia Ranks 4th Among National Life Sciences Markets in New Colliers Report
In the recently released Colliers 2024 Life Sciences Report, Philadelphia ranked #4 nationwide, with Boston, the San Francisco Bay Area and San Diego ranking first, second and third, respectively.
New Method Created for Improving the Resolution of Routine Medical Images
This novel method improves resolution of routine low resolution clinical images, saves MR scan time, and reduces radiation dosage levels for CT scanning.
Moderna Receives FDA Approval for RSV Vaccine Based on Penn Technology
RSV is a highly contagious seasonal respiratory virus and a leading cause of lower respiratory tract infections and pneumonia.
Penn Arts and Sciences’ MindCORE Neuroimaging Facility at Pennovation Works
The machine is the centerpiece of the new Neuroimaging Facility where scientists will study the mind-brain connection in-depth.